Allocentric Memory as a Novel Measure of Cognitive Inefficiency: Sensitivity in Multiple Sclerosis (MS) Subjects and Relationship With Resting State Functional MRI
| Status: | Recruiting |
|---|---|
| Conditions: | Neurology, Neurology, Multiple Sclerosis |
| Therapuetic Areas: | Neurology, Other |
| Healthy: | No |
| Age Range: | 18 - 55 |
| Updated: | 4/21/2016 |
| Start Date: | April 2014 |
| End Date: | April 2017 |
| Contact: | Franklin C Brown, Ph.D. |
| Email: | franklin.brown@yale.edu |
| Phone: | 203-785-5335 |
The goals of this study are to 1. Investigate the sensitivity of allocentric visual memory
when compared to more established measures of cognition in identifying cognitive
difficulties among MS subjects when compared to controls. 2. Determine which cognitive test
variable will be most strongly associated with self and informant reports of cognition. 3.
Determine which MRI metric will be most strongly related to neuropsychological test
performance 4. Determine the degree to which allocentric visual memory is related to
functional connectivity on fMRI.
when compared to more established measures of cognition in identifying cognitive
difficulties among MS subjects when compared to controls. 2. Determine which cognitive test
variable will be most strongly associated with self and informant reports of cognition. 3.
Determine which MRI metric will be most strongly related to neuropsychological test
performance 4. Determine the degree to which allocentric visual memory is related to
functional connectivity on fMRI.
This is a cross-sectional, case-control, observational experimental design. The study will
enroll subjects with multiple sclerosis (MS) and age/gender matched on a battery of
neuropsychological cognitive tests and self-report measures of cognition.
enroll subjects with multiple sclerosis (MS) and age/gender matched on a battery of
neuropsychological cognitive tests and self-report measures of cognition.
Inclusion Criteria:
- 18-55 years old
- Right handed
- Capacity to provide informed consent and sign consent
- Diagnosis of Relapsing Remitting MS that meets the revised McDonald Criteria (2010)
within the last 10 years
- EDSS 0- 5.5
Exclusion Criteria:
- Diagnosis of primary progressive MS
- Contraindications for MRI
- Subjects required to take medications known to either benefit or adversely affect
cognition at the time of testing and impact neuroimaging
- Non-MS neurological disorders
- Other medical or psychiatric disorders likely to affect cognitive performance
- Active immunodeficiency, chronic infections, or history or progressive multifocal
leukoencephalopathy
- Individuals with severe level of depression on the BDI-II or severe anxiety on the
BAI
- MS subjects who are actively experiencing acute exacerbation in symptoms and they
must be at least 4 weeks free of steroid medication, are currently taking a
chemotherapy agent, or have changed medication in the last two months
- Subjects who fail symptom validity measures during neuropsychological testing will be
excluded
We found this trial at
1
site
Yale University Yale's roots can be traced back to the 1640s, when colonial clergymen led...
Click here to add this to my saved trials
